Form 8-K Bioventus Inc. For: May 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Wall Street gains ground on healthcare stocks rally, oil retreat
- Brent slips as Iran president discusses mediation with Pakistan army chief
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
- Cerebras Systems falls as TD Cowen cuts price target
- Nasdaq climbs as chip and AI-linked stocks bounce back
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
- 3M issues warrant to Amazon in $6B data center product deal
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
Bioventus reiterates 2026 guidance after FDA device reclassification
May 21, 2026 5:14 PM EDTBioventus Inc. (NASDAQ: BVS) said it expects to maintain its 2026 financial guidance following regulatory changes affecting its bone healing device.
The U.S. Food and Drug Administration issued a final order on April 16, 2026, reclassifying non-invasive bone growth stimulators from Class III to Class II devices.... More



